JP Morgan analyst Ranjan Sharma downgrades TDCX (NYSE:TDCX) from Overweight to Neutral and lowers the price target from $14.1 to $12.1.
Analyst Ratings for Blueprint Medicines
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…